EMAIL THIS PAGE TO A FRIEND

Die Pharmazie

In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.


PMID 22957434

Abstract

A novel osmotic pump tablet with ethyl cellulose (EC) and polyvinyl pyrrolidone (PVP) as the semipermeable membrane and isosorbide-5-mononitrate (5-ISMN) as the model drug was formulated in this study. Zero order release kinetics were attained by avoiding aging during storage. Drug release increased with an increase in the percentage of PVP K30 in the semipermeable membrane. However, drug release decreased with increased coating weight. Drug release rates decreased continuously for tablets coated with EC/PEG4000 and cellulose acetate (CA)/PEG4000. This tendency was more marked with longer storage time. However, there was little change in drug release rates for tablets with a semipermeable membrane of EC/PVP K30 at 6, 12 or 24 months. The weight loss test also validated the results mentioned above. The relative bioavailability of the osmotic-pump tablets against the reference formulation in single and multiple dose regimens was 116.7 and 106.5, respectively. This means that the bioavailability of osmotic pump tablets using PVP as the plasticiser was equal to that of the reference formulation. In general, 5-ISMN osmotic pump tablets with a semipermeable membrane composed of EC/PVP K30 may be useful in providing constant drug delivery with minimum fluctuations during longer storage time.